Phase II Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy Plus Dasatinib (NSC 732517, IND 73969) and Continuation Therapy With Dasatinib Alone in Newly Diagnosed Patients With Core Binding Factor Acute Myeloid Leukemia (AML)
Latest Information Update: 03 Mar 2023
At a glance
- Drugs Dasatinib (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms Alliance
- 03 Aug 2022 Status changed from active, no longer recruiting to completed.
- 16 Jul 2019 Planned End Date changed from 1 Jul 2015 to 1 Jun 2020.
- 26 Dec 2015 Planned primary completion date changed from 1 Jul 2013 to 1 Jul 2015, according to ClinicalTrials.gov record.